Want to see AU:NOX full AI Analyst Report?
Noxopharm Ltd. (NOX) AI Stock Analysis
Noxopharm Ltd.
(ASX:NOX)
The overall score is constrained primarily by the company’s fragile financial position, including persistent losses, negative equity, shrinking assets and ongoing cash burn, which together signal elevated balance‑sheet and funding risk. Technical indicators reinforce this cautious view, with the share price below all key moving averages and weak momentum suggesting a continuing downtrend rather than a confirmed recovery. Valuation offers limited support, as a negative P/E and absence of dividends mean the stock’s appeal depends largely on speculative future upside rather than current earnings or income.
Noxopharm Ltd. (NOX) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 14.75M
- Dividend Yield
- ―
- Average Volume (3M)
- 88.38K
- Price to Earnings (P/E)
- -3.1
- Beta (1Y)
- 1.20
- Revenue Growth
- ―
- EPS Growth
- 10.18%
- Country
- Australia
- Employees
- 8
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Noxopharm Ltd. Business Overview & Revenue Model
Company Description
Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy des...
Noxopharm Ltd. Financial Statement Overview
Summary
Financial performance is very weak, with structurally loss‑making operations, deeply negative margins, shrinking assets, negative shareholders’ equity, rising debt reliance, and persistent, volatile cash burn, all pointing to a fragile balance sheet and high funding risk.
Income Statement
28NegativeBalance Sheet
12Very NegativeCash Flow
20Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 1.43M | 2.82M | 2.40M | 6.01M | 5.43M |
| Gross Profit | -1,743 | -1,743 | -1.45M | -534.81K | 5.86M | 5.17M |
| EBITDA | -4.85M | -4.85M | -5.38M | -5.95M | -20.85M | -23.70M |
| Net Income | -4.46M | -4.46M | -4.88M | -3.58M | -15.06M | -18.67M |
Balance Sheet | ||||||
| Total Assets | 1.84M | 1.84M | 4.58M | 6.78M | 10.13M | 26.59M |
| Cash, Cash Equivalents and Short-Term Investments | 293.57K | 293.57K | 1.55M | 2.32M | 3.01M | 14.01M |
| Total Debt | 4.57M | 4.57M | 2.48M | 0 | 0 | 160.62K |
| Total Liabilities | 5.48M | 5.48M | 3.89M | 1.29M | 1.06M | 2.48M |
| Stockholders Equity | -3.65M | -3.65M | 689.96K | 5.50M | 9.07M | 24.12M |
Cash Flow | ||||||
| Free Cash Flow | -2.71M | -2.71M | -5.82M | -684.31K | -10.95M | -13.73M |
| Operating Cash Flow | -2.71M | -2.71M | -5.82M | -684.31K | -10.95M | -13.73M |
| Investing Cash Flow | 0 | 0 | 2.48M | 0 | 123.51K | 0 |
| Financing Cash Flow | 1.45M | 1.45M | 2.60M | 0 | -178.09K | 975.73K |
Noxopharm Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NOX, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.07, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 36.02 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NOX.
Noxopharm Ltd. Peers Comparison
Overall Rating
AU:TLX53Neutral
AU:PTX44Neutral
AU:CU642Neutral
AU:RAC42Neutral
AU:RAD42Neutral- AU:NOX42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:TLX | 53Neutral | AUD 4.47B | 94.59 | 7.24% | ― | 26.66% | 179.32% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:PTX | 44Neutral | AUD 60.62M | -7.68 | -44.93% | ― | ― | 25.27% |
| AU:CU6 | 42Neutral | AUD 585.74M | -4.96 | -51.15% | ― | ― | -44.83% |
| AU:RAC | 42Neutral | AUD 302.93M | -23.67 | -36.95% | ― | ― | -125.09% |
| AU:RAD | 42Neutral | AUD 23.55M | -0.19 | -144.24% | ― | -23.82% | 12.36% |
| AU:NOX | 42Neutral | AUD 15.05M | -3.14 | 186.62% | ― | ― | 10.18% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:NOX | Noxopharm Ltd. | 0.05 | -0.04 | -47.83% | |
| AU:PTX | Prescient Therapeutics Limited | 0.05 | 0.01 | 11.11% | |
| AU:TLX | Telix Pharmaceuticals Ltd. | 13.08 | -2.67 | -16.95% | |
| AU:RAC | Race Oncology Ltd. | 1.47 | -1.84 | -55.59% | |
| AU:CU6 | Clarity Pharmaceuticals Ltd. | 1.48 | -3.36 | -69.42% | |
| AU:RAD | Radiopharm Theranostics Limited | 0.01 | -0.01 | -58.33% |
Noxopharm Ltd. Corporate Events
Noxopharm Proposes Issue of 625,000 Options
Noxopharm Limited has proposed issuing 625,000 options under a placement or other issue, with an exercise price of $0.063 and expiry on 1 November 2029. The securities are scheduled for issue on 24 December 2026, with a class code yet to be confirmed...
Noxopharm Advances Lupus and Immuno-Oncology Programs
Noxopharm advanced its clinical and research programs during the quarter, announcing an extension study of topical SOF-SKN in cutaneous lupus erythematosus after positive healthy-volunteer results. The company also reported preclinical evidence that...
Noxopharm Details Proposed Placement of Shares and Options
Noxopharm Ltd.’s industry, primary products and market focus are not specified in the release. The company outlines a proposed placement comprising 8,928,571 ordinary shares, 8,928,571 options expiring 1 November 2027 with a $0.042 exercise pri...
Noxopharm Proposes Placement of Shares and Options
Noxopharm Limited proposed a placement of 26,785,714 fully paid ordinary shares, 26,785,714 options expiring November 1, 2027, exercisable at $0.042, and 26,785,714 options expiring November 1, 2029, exercisable at $0.063. The proposed securities iss...
Noxopharm Raises Funds to Advance Sofra Pipeline
Noxopharm is developing targeted synthetic RNA medicines through its proprietary Sofra platform, which converts natural RNA immune-control mechanisms into potential treatments for chronic inflammation, autoimmune diseases and cancer. Its lead SOF-SKN...
Noxopharm Seeks Voluntary Suspension Ahead of Capital Raising Announcement
Noxopharm Limited has requested that trading in its shares be voluntarily suspended on the ASX, and the exchange has implemented the suspension under Listing Rule 17.2. The halt will remain in place until either the company releases a pending announc...
Noxopharm Seeks Trading Halt Ahead of Material Capital Raising
Noxopharm Limited has requested a trading halt on its securities on the Australian Securities Exchange, with the halt to remain in place until either normal trading resumes on 29 October 2026 or the company issues a pending announcement. The move und...
FDA feedback de-risks Noxopharm’s SOF-SKN Phase II trial plans
Noxopharm has received supportive feedback from the U.S. Food and Drug Administration on its planned Phase II clinical trial for SOF-SKN™, its autoimmune disease drug candidate, providing regulatory clarity on trial design, manufacturing and no...
Noxopharm narrows loss as Sofra platform advances through trials, partnerships and new CEO
Noxopharm Ltd reported a narrowed full-year loss of $4.46 million for the year ended 30 June 2026, as it continued to invest heavily in its Sofra drug design platform and lead candidate SOF-SKN. The company did not declare dividends, reflecting its f...
Noxopharm Advances SOF-SKN into CLE Extension Study to Target Autoimmune Skin Market
Australian biotech Noxopharm is advancing its lead topical therapy SOF-SKN, developed from its Sofra immune-modulation platform, for autoimmune skin diseases including cutaneous lupus erythematosus. The company is targeting unmet needs in chronic inf...
Noxopharm outlines precision therapy pipeline and clarifies trial links
Noxopharm has released an investor presentation outlining its development focus on precision therapies targeting chronic inflammation, autoimmune conditions and cancer, highlighting its SOF-SKN, SOF-CAN and SOF-VAC programs. The company emphasises th...
Noxopharm’s Sofra Oligos Show Promise in Reducing mRNA Vaccine Reactogenicity
Noxopharm has reported promising data on its novel oligonucleotides from the Sofra platform, presented by CSL at the International Society for Respiratory Viruses’ Options for the Control of Influenza XIII Conference in Washington, D.C. The stu...
Noxopharm Narrows Annual Loss but Net Tangible Assets Turn Negative
Noxopharm Limited reported a reduced annual loss of $4.46 million for the year ended 30 June 2026, an 8.8% improvement on the prior year’s $4.88 million loss, indicating modest progress in narrowing its deficit. The company did not declare or p...
Noxopharm Preclinical Data Bolsters Sofra Immuno-Oncology Platform
Noxopharm has reported new preclinical data showing its Sofra technology can activate immune cells in response to dying cancer cells, strengthening its immuno-oncology proposition. In studies with the Hudson Institute of Medical Research, significant...
Noxopharm Data Validate TLR8-Targeted Oligonucleotide Cancer Strategy
Noxopharm has reported new preclinical data showing its synthetic RNA oligonucleotides can convert normally immune-silent cellular RNA into a potent trigger for Toll-like receptor 8, a key immune sensor. In vitro, combining total cellular RNA with a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 17, 2026